Attovia Therapeutics (ATTO) Stock Forecast: StockMap's 2-Week Call
ATTO stock forecast: StockMap's model leans Underperform on Attovia Therapeutics for the two weeks after the Nov 16 close, toward ATTO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 5 two-week windows on ATTO since Aug 26; by chance, a call on the same dates was right 62% of the time.
Attovia Therapeutics last closed at $14.72, -2.71% on the session.
Against the IVW growth benchmark the position is -0.09% over the forecast window.
Attovia Therapeutics' market cap is $672.89M as of November 16, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where ATTO sits: sized by market cap, coloured by the day's move.
The read is built from 11 underlying insights — 1 bullish and 10 bearish.
Agreement across those insights is 91%.
40 daily calls for ATTO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Attovia Therapeutics in the 0th percentile on return on equity, where 100 is best.
Attovia Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Attovia Therapeutics as the 150th largest of the 392 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 191 Moderate Underperform, 151 Neutral, 36 Strong Underperform and 14 Moderate Outperform.
On that composite Attovia Therapeutics ranks 303rd of 392 in the group, against a group median of -0.27.